Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[ 18 F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios.

ImmunoPET agents are being investigated to assess the status of epidermal growth factor receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit from HER2-targeted therapies and monitoring their progress after these treatments. We have been exploring the use of single domain antibody fragments (sdAbs) labeled with F-18 using residualizing prosthetic agents for this purpose. In this study, we have labeled two sdAbs that bind to different domains on the HER2 receptor, 2Rs15d and 5F7, using 2,3,5,6-tetrafluorophenyl 6-[F-18]-fluoronicotinate ([F-18]TFPFN) and evaluated their HER2 targeting properties in vitro and in vivo. The overall decay-corrected radiochemical yield for the synthesis of [F-18]TFPFN-2Rs15d and [F-18]TFPFN-5F7 was 5.7 +/- 3.6 and 4.0 +/- 2.0%, respectively. The radiochemical purity of labeled sdAbs was >95%, immunoreactive fractions were about 60%, and affinity was in the low nanomolar range. Intracellularly trapped activity from [F-18]TFPFN-2Rs15d and [F-18]TFPFN-5F7 in HER2-expressing SKOV-3 ovarian and BT474M1 breast carcinoma cells were similar to the sdAbs labeled using the previously validated radioiodination residualizing prosthetic agents N-succinimidyl 4-guanidinomethyl-3-[I-125]iodobenzoate ([I-125]SGMIB) and N-succinimidyl 3-guanidinomethyl-5-[I-125]iodobenzoate (iso-[I-125]SGMIB). Intracellular activity was about 2-fold higher for radiolabeled 5F7 compared with 2Rs15d for both F-18 and I-125. While tumor uptake of both [F-18]TFPFN-2Rs15d and [F-18]TFPFN-5F7 was comparable to those for the coadministered I-125-labeled sdAb, renal uptake of the F-18-labeled sdAbs was substantially lower. In microPET images, the tumor was clearly delineated in SKOV-3 and BT474 xenograft-bearing athymic mice with low levels of background activity in normal tissues, except the bladder. These results indicate that the [F-18]TFPFN prosthetic group could be a valuable reagent for developing sdAb-based immunoPET imaging agents.